Structure via PubChem · Public domain (PubChem)
xaliproden
Sign in to saveAlso known as 1,2,3,6-tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine, 1,2,3,6-tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine
Xaliproden (codenamed SR57746) is a drug which acts as a 5HT1A agonist. It has neurotrophic and neuroprotective effects in vitro, and has been proposed for use in the treatment of several neurodegenerative conditions including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.
Chemical data
- Formula
- C24H22F3N
- Molecular weight
- 381.4 g/mol
- IUPAC name
- 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine
- SMILES
- C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3
- InChIKey
- WJJYZXPHLSLMGE-UHFFFAOYSA-N
- XLogP
- 6.2
- Polar surface area
- 3.2 Ų
- H-bond donors
- 0
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- colorectal neoplasm, Alzheimer disease
via ChEMBL · EBI
Research
51 papers- Xaliproden lessens oxaliplatin-mediated neuropathy.The Lancet. Oncology · 2006
- Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis.Current Alzheimer research · 2006
- Xaliproden: SR 57746, SR 57746A, xaliproden hydrochloride, xaliprodene.Drugs in R&D · 2003
- The Xaliproden Nanoscale Zirconium-Porphyrin Metal-Organic Framework (XAL-NPMOF) Promotes Photoreceptor Regeneration Following Oxidative and Inflammatory Insults.International journal of nanomedicine · 2024
- SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases.Expert opinion on investigational drugs · 2009
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 381.170434
Show 4 more facts
- chemical formula
- C₂₄H₂₂F₃N
- canonical SMILES
- C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3
- World Health Organisation international non-proprietary name
- xaliproden
- physically interacts with
- 5-hydroxytryptamine receptor 1A
via Wikidata · CC0
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Xaliproden (codenamed SR57746) is a drug which acts as a 5HT1A agonist. It has neurotrophic and neuroprotective effects in vitro, and has been proposed for use in the treatment of several neurodegenerative conditions including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.
Development of xaliproden for these two indications was discontinued in 2007 following analysis of Phase III data. While the drug did show an effect on hippocampal volume (suggesting perhaps a slowing of cell loss), there was insufficient evidence for efficacy in counteracting Alzheimer's related cognitive decline. Similarly while there were some indicators of efficacy in ALS, including a small but clinically noteworthy effect on some functional parameters, the overall benefit did not reach statistical significance when results across several Phase III trials were averaged. Xaliproden remains under investigation for treatment of chemotherapy-induced peripheral neuropathy.
Excerpted from Wikipedia’s “xaliproden” article, available under the CC BY-SA 4.0 licence.
Available in 7 languages
via Wikidata sitelinks · CC0